AAAAAA

   
Results: 1-20 |
Results: 20
An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations - Fluorescent mutation detection (F-MD)
Authors: Edwards, SM Kote-Jarai, Z Hamoudi, R Eeles, RA
Citation: Sm. Edwards et al., An improved high throughput heteroduplex mutation detection system for screening BRCA2 mutations - Fluorescent mutation detection (F-MD), HUM MUTAT, 17(3), 2001, pp. 220-232
Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women
Authors: Mitchell, G Trott, PA Morris, L Coleman, N Sauter, E Eeles, RA
Citation: G. Mitchell et al., Cellular characteristics of nipple aspiration fluid during the menstrual cycle in healthy premenopausal women, CYTOPATHOLO, 12(3), 2001, pp. 184-196
CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers
Authors: Kadouri, L Easton, DF Edwards, S Hubert, A Kote-Jarai, Z Glaser, B Durocher, F Abeliovich, D Peretz, T Eeles, RA
Citation: L. Kadouri et al., CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers, BR J CANC, 85(1), 2001, pp. 36-40
Future possibilities in the prevention of breast cancer - Intervention strategies in BRCA1 and BRCA2 mutation carriers
Authors: Eeles, RA
Citation: Ra. Eeles, Future possibilities in the prevention of breast cancer - Intervention strategies in BRCA1 and BRCA2 mutation carriers, BREAST CA R, 2(4), 2000, pp. 283-290
Molecular markers for predicting prostate cancer stage and survival
Authors: Dunsmuir, WD Gillett, CE Meyer, LC Young, MP Corbishley, C Eeles, RA Kirby, RS
Citation: Wd. Dunsmuir et al., Molecular markers for predicting prostate cancer stage and survival, BJU INT, 86(7), 2000, pp. 869-878
High risk genes predisposing to prostate cancer development - do they exist?
Authors: Singh, R Eeles, RA Durocher, F Simard, J Edwards, S Badzioch, M Kote-Jarai, Z Teare, D Ford, D Dearnaley, D Ardern-Jones, A Murkin, A Dowe, A Shearer, R Kelly, J Labrie, F Easton, D Narod, SA Tonin, PN Foulkes, WD
Citation: R. Singh et al., High risk genes predisposing to prostate cancer development - do they exist?, PROSTATE C, 3(4), 2000, pp. 241-247
Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer
Authors: Brown, J Coulthard, A Dixon, AK Dixon, JM Easton, DF Eeles, RA Evans, DGR Gilbert, FG Hayes, C Jenkins, JPR Leach, MO Moss, SM Padhani, AP Pointon, LJ Ponder, BAJ Sloane, JP Turnbull, LW Walker, LG Warren, RML Watson, W
Citation: J. Brown et al., Rationale for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer, BREAST, 9(2), 2000, pp. 72-77
Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer
Authors: Brown, J Coulthard, A Dixon, AK Dixon, JM Easton, DF Eeles, RA Evans, DGR Gilbert, FG Hayes, C Jenkins, JPR Leach, MO Moss, SM Padhani, AP Pointon, LJ Ponder, BAJ Sloane, JP Turnbull, LW Walker, LG Warren, RML Watson, W
Citation: J. Brown et al., Protocol for a national multi-centre study of magnetic resonance imaging screening in women at genetic risk of breast cancer, BREAST, 9(2), 2000, pp. 78-82
Chemoprevention options for BRCA1 and BRCA2 mutation carriers
Authors: Eeles, RA Powles, TJ
Citation: Ra. Eeles et Tj. Powles, Chemoprevention options for BRCA1 and BRCA2 mutation carriers, J CL ONCOL, 18(21), 2000, pp. 93S-99S
Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study
Authors: Brown, J Buckley, D Coulthard, A Dixon, AK Dixon, JM Easton, DF Eeles, RA Evans, DGR Gilbert, FG Graves, M Hayes, C Jenkins, JPR Jones, AP Keevil, SF Leach, MO Liney, GP Moss, SM Padhani, AR Parker, GJM Pointon, LJ Ponder, BAJ Redpath, TW Sloane, JP Turnbull, LW Walker, LG Warren, RML
Citation: J. Brown et al., Magnetic resonance imaging screening in women at genetic risk of breast cancer: imaging and analysis protocol for the UK multicentre study, MAGN RES IM, 18(7), 2000, pp. 765-776
No evidence of germline PTEN mutations in familial prostate cancer
Authors: Forrest, MS Edwards, SM Hamoud, RA Dearnaley, DP Arden-Jones, A Dowe, A Kelly, J Teara, MD Easton, DF Knowles, MA Bishop, DT Eeles, RA
Citation: Ms. Forrest et al., No evidence of germline PTEN mutations in familial prostate cancer, J MED GENET, 37(3), 2000, pp. 210-212
The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer
Authors: Gayther, SA de Foy, EAF Harrington, P Pharoah, P Dunsmuir, WD Edwards, SM Gillett, C Ardern-Jones, A Dearnaley, DP Easton, DF Ford, D Shearer, RJ Kirby, RS Dowe, AL Kelly, J Stratton, MR Ponder, BAJ Barnes, D Eeles, RA
Citation: Sa. Gayther et al., The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer, CANCER RES, 60(16), 2000, pp. 4513-4518
The value of rapid functional assays of germline p53 status in LFS and LFLfamilies
Authors: Camplejohn, RS Sodha, N Gilchrist, R Lomax, ME Duddy, PM Miner, C Alarcon-Gonzalez, P Barnes, DM Eeles, RA
Citation: Rs. Camplejohn et al., The value of rapid functional assays of germline p53 status in LFS and LFLfamilies, BR J CANC, 82(6), 2000, pp. 1145-1148
Genetic predisposition to prostate cancer
Authors: Eeles, RA
Citation: Ra. Eeles, Genetic predisposition to prostate cancer, PROSTATE C, 2(1), 1999, pp. 9-15
Screening for hereditary cancer and genetic testing, epitomised by breast cancer
Authors: Eeles, RA
Citation: Ra. Eeles, Screening for hereditary cancer and genetic testing, epitomised by breast cancer, EUR J CANC, 35(14), 1999, pp. 1954-1962
Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10
Authors: Stone, JG Eeles, RA Sodha, N Murday, V Sheriden, E Houlston, RS
Citation: Jg. Stone et al., Analysis of Li-Fraumeni syndrome and Li-Fraumeni-like families for germline mutations in Bcl10, CANCER LETT, 147(1-2), 1999, pp. 181-185
Management of breast cancer in BRCA1/2 mutation carriers
Authors: Eeles, RA Camplejohn, R Peacock, J McMillan, T
Citation: Ra. Eeles et al., Management of breast cancer in BRCA1/2 mutation carriers, DIS MARKER, 15(1-3), 1999, pp. 204-204
Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer
Authors: Hodgson, SV Heap, E Cameron, J Ellis, D Mathew, CG Eeles, RA Solomon, E Lewis, CM
Citation: Sv. Hodgson et al., Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer, J MED GENET, 36(5), 1999, pp. 369-373
Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival
Authors: Edwards, SM Badzioch, MD Minter, R Hamoudi, R Collins, N Ardern-Jones, A Dowe, A Osborne, S Kelly, J Shearer, R Easton, DF Saunders, GF Dearnaley, DP Eeles, RA
Citation: Sm. Edwards et al., Androgen receptor polymorphisms: Association with prostate cancer risk, relapse and overall survival, INT J CANC, 84(5), 1999, pp. 458-465
BRCA1, BRCA2 and their possible function in DNA damage response
Authors: Kote-Jarai, Z Eeles, RA
Citation: Z. Kote-jarai et Ra. Eeles, BRCA1, BRCA2 and their possible function in DNA damage response, BR J CANC, 81(7), 1999, pp. 1099-1102
Risultati: 1-20 |